JP2023012515A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023012515A5 JP2023012515A5 JP2022175995A JP2022175995A JP2023012515A5 JP 2023012515 A5 JP2023012515 A5 JP 2023012515A5 JP 2022175995 A JP2022175995 A JP 2022175995A JP 2022175995 A JP2022175995 A JP 2022175995A JP 2023012515 A5 JP2023012515 A5 JP 2023012515A5
- Authority
- JP
- Japan
- Prior art keywords
- human subject
- composition
- increasing
- subject
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003205 muscle Anatomy 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 4
- 102000018997 Growth Hormone Human genes 0.000 claims 3
- 108010051696 Growth Hormone Proteins 0.000 claims 3
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 3
- 108010056852 Myostatin Proteins 0.000 claims 3
- 239000000122 growth hormone Substances 0.000 claims 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 229940122199 Insulin secretagogue Drugs 0.000 claims 2
- 210000000577 adipose tissue Anatomy 0.000 claims 2
- 210000003486 adipose tissue brown Anatomy 0.000 claims 2
- 210000000593 adipose tissue white Anatomy 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000004190 glucose uptake Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 229960000698 nateglinide Drugs 0.000 claims 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 108010059616 Activins Proteins 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010065687 Bone loss Diseases 0.000 claims 1
- 206010016803 Fluid overload Diseases 0.000 claims 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 1
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims 1
- 102100026818 Inhibin beta E chain Human genes 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 239000000488 activin Substances 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000037182 bone density Effects 0.000 claims 1
- 235000021236 calorie-restricted diet Nutrition 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 101150055782 gH gene Proteins 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000002641 glycemic effect Effects 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 210000001596 intra-abdominal fat Anatomy 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 230000037323 metabolic rate Effects 0.000 claims 1
- 229960003365 mitiglinide Drugs 0.000 claims 1
- WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 230000037081 physical activity Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 229960002354 repaglinide Drugs 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024189463A JP2025020230A (ja) | 2017-01-06 | 2024-10-29 | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443455P | 2017-01-06 | 2017-01-06 | |
| US62/443,455 | 2017-01-06 | ||
| EP17150586 | 2017-01-06 | ||
| EP17150586.0 | 2017-01-06 | ||
| US201762530311P | 2017-07-10 | 2017-07-10 | |
| US62/530,311 | 2017-07-10 | ||
| US201762608069P | 2017-12-20 | 2017-12-20 | |
| US62/608,069 | 2017-12-20 | ||
| PCT/US2018/012686 WO2018129395A1 (en) | 2017-01-06 | 2018-01-05 | Methods for treating metabolic diseases by inhibiting myostatin activation |
| JP2019536836A JP7198757B2 (ja) | 2017-01-06 | 2018-01-05 | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536836A Division JP7198757B2 (ja) | 2017-01-06 | 2018-01-05 | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024189463A Division JP2025020230A (ja) | 2017-01-06 | 2024-10-29 | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023012515A JP2023012515A (ja) | 2023-01-25 |
| JP2023012515A5 true JP2023012515A5 (cg-RX-API-DMAC10.html) | 2023-08-09 |
Family
ID=61022453
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536836A Active JP7198757B2 (ja) | 2017-01-06 | 2018-01-05 | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
| JP2022175995A Pending JP2023012515A (ja) | 2017-01-06 | 2022-11-02 | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
| JP2024189463A Pending JP2025020230A (ja) | 2017-01-06 | 2024-10-29 | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536836A Active JP7198757B2 (ja) | 2017-01-06 | 2018-01-05 | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024189463A Pending JP2025020230A (ja) | 2017-01-06 | 2024-10-29 | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11155611B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP4218817A3 (cg-RX-API-DMAC10.html) |
| JP (3) | JP7198757B2 (cg-RX-API-DMAC10.html) |
| AU (3) | AU2018205270B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3088855A1 (cg-RX-API-DMAC10.html) |
| DK (1) | DK3565592T5 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2944357T3 (cg-RX-API-DMAC10.html) |
| FI (1) | FI3565592T3 (cg-RX-API-DMAC10.html) |
| HR (1) | HRP20230308T1 (cg-RX-API-DMAC10.html) |
| HU (1) | HUE061656T2 (cg-RX-API-DMAC10.html) |
| PL (1) | PL3565592T3 (cg-RX-API-DMAC10.html) |
| RS (1) | RS64159B1 (cg-RX-API-DMAC10.html) |
| SI (1) | SI3565592T1 (cg-RX-API-DMAC10.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016073853A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| EA038146B1 (ru) | 2015-09-15 | 2021-07-13 | Сколар Рок, Инк. | Антитела к про-/латентному миостатину и их применения |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| DK4358995T3 (da) * | 2021-06-23 | 2026-02-02 | Scholar Rock Inc | Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser |
| CN120677175A (zh) | 2022-12-22 | 2025-09-19 | 供石公司 | 肌生成抑制蛋白活化的选择性和强效抑制剂 |
| WO2025243299A1 (en) * | 2024-05-20 | 2025-11-27 | Technion Research & Development Foundation Limited | Nutrient-based formulations usable in treating muscle atrophy |
| TW202617762A (zh) * | 2024-07-04 | 2026-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合潛伏肌生長抑制素的抗原結合分子及其醫藥用途 |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| DE69534468T2 (de) | 1994-07-08 | 2006-07-13 | The Johns Hopkins University School Of Medicine | Wachstums-differenzierungsfaktor-11 |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| WO2000053211A2 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| PL357017A1 (en) | 2000-01-28 | 2004-07-12 | Novo Nordisk A/S | Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| AU2011244851A1 (en) | 2000-07-27 | 2011-11-24 | The John Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US8455627B2 (en) | 2001-10-05 | 2013-06-04 | Affimed Therapeutics, Ag | Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa |
| ATE364632T1 (de) | 2001-10-05 | 2007-07-15 | Affimed Therapeutics Ag | Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation |
| US20040131614A1 (en) | 2002-07-19 | 2004-07-08 | Abbott Biotechnology Ltd. | Treatment of pulmonary disorders using TNFalpha inhibitor |
| AU2003267246A1 (en) | 2002-09-16 | 2004-04-30 | The Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| AU2003301195B2 (en) * | 2002-12-20 | 2010-01-07 | Amgen Inc. | Binding agents which inhibit myostatin |
| WO2005066204A2 (en) | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| CA2558478A1 (en) * | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors and uses thereof |
| US20070178095A1 (en) * | 2004-03-23 | 2007-08-02 | Eli Lilly And Company | Anti-myostatin antibodies |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| EP1755648A2 (en) | 2004-05-27 | 2007-02-28 | Acceleron Pharma Inc. | Cerberus/coco derivatives and uses thereof |
| CA2575791A1 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| EP2361933A3 (en) | 2005-01-26 | 2012-05-02 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| US20060216279A1 (en) | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| TW200724548A (en) * | 2005-04-25 | 2007-07-01 | Pfizer | Antibodies to myostatin |
| US7888486B2 (en) * | 2005-08-19 | 2011-02-15 | Wyeth Llc | Antagonist antibodies against GDF-8 |
| KR101135220B1 (ko) | 2005-10-06 | 2012-04-24 | 일라이 릴리 앤드 캄파니 | 항-마이오스타틴 항체 |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| WO2007061995A2 (en) | 2005-11-21 | 2007-05-31 | Novartis Ag | Biomarkers for statin-induced myopathy or rhabdomyolysis |
| US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| BRPI0715072A2 (pt) * | 2006-08-03 | 2013-06-25 | Orico Ltd | antagonistas de miostatina |
| HRP20130320T1 (en) * | 2006-09-05 | 2013-05-31 | Eli Lilly And Company | Anti-myostatin antibodies |
| WO2008067480A2 (en) | 2006-11-29 | 2008-06-05 | Nationwide Children's Hospital | Myostatin inhibition for enhancing muscle and/or improving muscle function |
| JP2010519256A (ja) | 2007-02-23 | 2010-06-03 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 免疫疾患を治療するために、ＨＬＡ−Ｅ／Ｑａ−１拘束性ＣＤ８＋Ｔ細胞制御性経路を活性化または遮断する方法 |
| KR101531722B1 (ko) | 2007-03-30 | 2015-06-25 | 메르크 파텐트 게엠베하 | 음성 광학 분산도를 갖는 복굴절층 |
| AU2008260445A1 (en) | 2007-06-01 | 2008-12-11 | Biogen Idec Ma Inc. | Cripto binding molecules |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| TW201029662A (en) * | 2008-12-19 | 2010-08-16 | Glaxo Group Ltd | Novel antigen binding proteins |
| US8952130B2 (en) | 2009-02-24 | 2015-02-10 | The Salk Institute For Biological Studies | Designer ligands of TGF-β superfamily |
| ES2655877T3 (es) | 2009-04-27 | 2018-02-22 | Novartis Ag | Composiciones y métodos para aumentar el crecimiento muscular |
| MX355042B (es) | 2009-06-08 | 2018-04-02 | Acceleon Pharma Inc | Metodos para aumentar adipositos termogenicos. |
| US8945511B2 (en) * | 2009-06-25 | 2015-02-03 | Paul Weinberger | Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3 |
| NZ599604A (en) * | 2009-10-01 | 2014-07-25 | Myostin Therapeutics Pty Ltd | Synthetic myostatin peptide antagonists |
| EP3904391B1 (en) | 2010-03-10 | 2024-07-10 | Genmab A/S | Monoclonal antibodies against c-met |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| PH12013500315A1 (en) | 2010-08-16 | 2013-04-29 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
| WO2013071056A2 (en) | 2011-11-11 | 2013-05-16 | Duke University | Combination drug therapy for the treatment of solid tumors |
| US20130178454A1 (en) | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| WO2013165972A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
| MY177331A (en) | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| US20150284455A1 (en) | 2012-11-06 | 2015-10-08 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
| HRP20201914T1 (hr) | 2013-05-06 | 2021-01-22 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| EP2853898B1 (en) | 2013-09-27 | 2017-01-04 | Medizinische Hochschule Hannover | Analysis of myostatin in serum |
| US10004814B2 (en) | 2013-11-11 | 2018-06-26 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
| WO2015195094A1 (en) | 2014-06-17 | 2015-12-23 | Ember Therapeutics, Inc. | Anti-activin and nati-myostatin antibodies and methods of using the same |
| WO2016073853A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| WO2016073879A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| EA038146B1 (ru) | 2015-09-15 | 2021-07-13 | Сколар Рок, Инк. | Антитела к про-/латентному миостатину и их применения |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| PL4218804T3 (pl) * | 2016-06-13 | 2026-05-25 | Scholar Rock, Inc. | Stosowanie inhibitorów miostatyny i terapii skojarzonych |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
-
2018
- 2018-01-05 HR HRP20230308TT patent/HRP20230308T1/hr unknown
- 2018-01-05 PL PL18701237.2T patent/PL3565592T3/pl unknown
- 2018-01-05 EP EP23158609.0A patent/EP4218817A3/en active Pending
- 2018-01-05 RS RS20230295A patent/RS64159B1/sr unknown
- 2018-01-05 US US16/474,330 patent/US11155611B2/en active Active
- 2018-01-05 AU AU2018205270A patent/AU2018205270B2/en active Active
- 2018-01-05 ES ES18701237T patent/ES2944357T3/es active Active
- 2018-01-05 SI SI201830885T patent/SI3565592T1/sl unknown
- 2018-01-05 HU HUE18701237A patent/HUE061656T2/hu unknown
- 2018-01-05 JP JP2019536836A patent/JP7198757B2/ja active Active
- 2018-01-05 DK DK18701237.2T patent/DK3565592T5/da active
- 2018-01-05 FI FIEP18701237.2T patent/FI3565592T3/fi active
- 2018-01-05 CA CA3088855A patent/CA3088855A1/en active Pending
- 2018-01-05 EP EP18701237.2A patent/EP3565592B1/en active Active
-
2021
- 2021-09-22 US US17/448,389 patent/US20220106390A1/en not_active Abandoned
-
2022
- 2022-11-02 JP JP2022175995A patent/JP2023012515A/ja active Pending
- 2022-11-08 AU AU2022268305A patent/AU2022268305B2/en active Active
-
2024
- 2024-10-29 JP JP2024189463A patent/JP2025020230A/ja active Pending
-
2025
- 2025-03-19 US US19/083,831 patent/US20260035447A1/en active Pending
-
2026
- 2026-02-12 AU AU2026201037A patent/AU2026201037A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12616740B2 (en) | Methods of using a GIP/GLP1 co-agonist for therapy | |
| JP2024532619A5 (cg-RX-API-DMAC10.html) | ||
| US20080213288A1 (en) | Combined Use Of A Modulator Of CD3 And A GLP-1 Compound | |
| JP7512272B2 (ja) | Ａｌｋ２抗体及びその使用方法 | |
| CN102389413B (zh) | 用于治疗糖尿病的组合物及其应用 | |
| JP2017537894A (ja) | Ｇｌｐ−１ｒおよびｇｌｐ−２ｒ二重アゴニスト活性を有する組成物及びペプチド | |
| JP2020514295A5 (cg-RX-API-DMAC10.html) | ||
| EA013121B1 (ru) | Амилин и агонисты амилина для лечения психиатрических заболеваний и расстройств | |
| JP2024524159A5 (cg-RX-API-DMAC10.html) | ||
| JP2020500852A5 (cg-RX-API-DMAC10.html) | ||
| EP1515749A1 (en) | Combined use of a modulator of cd3 and a glp-1 compound | |
| FI3565592T3 (fi) | Metabolisten tautien hoitaminen estämällä myostatiinin aktivaatio | |
| JP2022542151A (ja) | ＦＧＦ２１ Ｆｃ融合タンパク質、ＧＬＰ－１ Ｆｃ融合タンパク質、それらの併用治療剤および使用 | |
| JP2020514305A5 (cg-RX-API-DMAC10.html) | ||
| JP2023510609A (ja) | Ｇｌｐ－１および／またはｇｌｐ－１類似体、ならびにインスリンおよび／またはインスリン類似体を含む併用療法 | |
| EA006881B1 (ru) | ПРИМЕНЕНИЕ АКТИВАТОРОВ gp130 ПРИ ДИАБЕТИЧЕСКОЙ НЕВРОПАТИИ | |
| US20070161551A1 (en) | Methods and compositions for the treatment of lipodystrophy | |
| CN121152634A (zh) | 用于治疗恶心和呕吐的方法和用途 | |
| KR20210013543A (ko) | 내피 세포 기능장애를 조절하기 위한 rps2 펩타이드의 용도 | |
| RU2804335C2 (ru) | Слитый белок fgf21 fc, слитый белок glp-1 fc и комбинированный терапевтический агент, включающий их, и их применение | |
| CA2552404A1 (en) | Methods and compositions for the treatment of lipodystrophy | |
| Hillegass et al. | Cardiopulmonary implications of specific diseases | |
| WO2025259957A1 (en) | Compositions and methods for improving insulin sensitivity | |
| AU2024311368A1 (en) | Glp-1 analog for use in the treatment of metabolic disorders | |
| US7781420B2 (en) | Use of clodronic acid for treatment podotrochlosis |